SCHEMBL884625

SCHEMBL884625

c1ccc(Nc2ccccc2CC(c2cccnc2)c2cccnc2)nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 12/20 0.53
KCNH2 Q12809 4/20 0.53
MEN1 O00255 1/20 0.49
MAPK10 P53779 1/20 0.49
GFER P55789 1/20 0.49
KMT2A Q03164 1/20 0.49
KDM4E B2RXH2 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CFTR P13569 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
GOPC Q9HD26 1/20 0.41
ITGB3 P05106 1/20 0.40
ITGB1 P05556 1/20 0.40
ITGAV P06756 1/20 0.40
ITGB6 P18564 1/20 0.40
TEAD4 Q15561 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL884872 0.90 KCNA5 (0.53) KCNA5KCNH2MEN1KMT2ACFTR
SCHEMBL884819 0.87 KCNA5 (0.53) KCNA5KCNH2KDM4EHTTNPSR1
SCHEMBL885079 0.86 KCNA5 (0.56) KCNA5KCNH2KDM4ECFTRSLC6A2
SCHEMBL884575 0.86 KCNA5 (0.52) KCNA5KCNH2KDM4ECFTRSLC6A2
SCHEMBL884632 0.85 KCNA5 (0.49) KCNA5KCNH2KDM4ECFTRSLC6A2
SCHEMBL884862 0.82 KCNA5 (0.57) KCNA5KCNH2KMT2AKDM4ECFTR
SCHEMBL884592 0.82 KCNA5 (0.46) KCNA5KCNH2MAPK10HTT
SCHEMBL884337 0.81 KCNA5 (0.60) KCNA5KCNH2KDM4ECFTRSLC6A2
SCHEMBL884331 0.80 KCNA5 (0.49) KCNA5KCNH2CFTRSLC6A2SLC6A4
SCHEMBL884751 0.80 KCNA5 (0.46) KCNA5KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US claimed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US claimed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP claimed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO claimed
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP disclosed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885MEN1 2152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.